Literature DB >> 18198210

A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120.

Alfredo Menendez1, Daniel A Calarese, Robyn L Stanfield, Keith C Chow, Chris N Scanlan, Renate Kunert, Herman Katinger, Dennis R Burton, Ian A Wilson, Jamie K Scott.   

Abstract

MAb 2G12 neutralizes HIV-1 by binding with high affinity to a cluster of high-mannose oligosaccharides on the envelope glycoprotein, gp120. Screening of phage-displayed peptide libraries with 2G12 identified peptides that bind specifically, with K(d)s ranging from 0.4 to 200 microM. The crystal structure of a 21-mer peptide ligand in complex with 2G12 Fab was determined at 2.8 A resolution. Comparison of this structure with previous structures of 2G12-carbohydrate complexes revealed striking differences in the mechanism of 2G12 binding to peptide vs. carbohydrate. The peptide occupies a site different from, but adjacent to, the primary carbohydrate-binding site on 2G12, and makes only slightly fewer contacts to the Fab than Man(9)GlcNAc(2) (51 vs. 56, respectively). However, only two antibody contacts with the peptide are hydrogen bonds in contrast to six with Man(9)GlcNAc(2), and only three of the antibody residues that interact with Man(9)GlcNAc(2) also contact the peptide. Thus, this mechanism of peptide binding to 2G12 does not support structural mimicry of the native carbohydrate epitope on gp120, since it neither replicates the oligosaccharide footprint on the antibody nor most of the contact residues. Moreover, 2G12.1 peptide is not an immunogenic mimic of the 2G12 epitope, since antisera produced against it did not bind gp120.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18198210      PMCID: PMC2430149          DOI: 10.1096/fj.07-8983com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  60 in total

1.  Initial studies of the molecular basis of peptide mimicry of group B streptococcal type III capsular polysaccharide.

Authors:  S H Pincus; S R Lepage; R F Jung; J G Massey; M Jaseja
Journal:  Int Rev Immunol       Date:  2001       Impact factor: 5.311

2.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody.

Authors:  Isaac J Krauss; Joseph G Joyce; Adam C Finnefrock; Hong C Song; Vadim Y Dudkin; Xudong Geng; J David Warren; Michael Chastain; John W Shiver; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2007-08-21       Impact factor: 15.419

4.  A molecular basis for functional peptide mimicry of a carbohydrate antigen.

Authors:  P Luo; G Canziani; G Cunto-Amesty; T Kieber-Emmons
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

5.  Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

Authors:  M B Zwick; L L Bonnycastle; A Menendez; M B Irving; C F Barbas; P W Parren; D R Burton; J K Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice.

Authors:  G B Lesinski; S L Smithson; N Srivastava; D Chen; G Widera; M A Westerink
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

7.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Characterization of oligopeptides that cross-react with carbohydrate-specific antibodies by real time kinetics, in-solution competition enzyme-linked immunosorbent assay, and immunological analyses.

Authors:  Paul J Brett; Harmale Tiwana; Ian M Feavers; Bambos M Charalambous
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  11 in total

1.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.

Authors:  Melita B Irving; Lisa Craig; Alfredo Menendez; Beechanahalli P Gangadhar; Marinieve Montero; Nienke E van Houten; Jamie K Scott
Journal:  Mol Immunol       Date:  2009-12-23       Impact factor: 4.407

4.  Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS.

Authors:  Kathryn Gomery; Sven Müller-Loennies; Cory L Brooks; Lore Brade; Paul Kosma; Franco Di Padova; Helmut Brade; Stephen V Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

5.  Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12.

Authors:  Yunji Wu; Anthony P West; Helen J Kim; Matthew E Thornton; Andrew B Ward; Pamela J Bjorkman
Journal:  Cell Rep       Date:  2013-12-05       Impact factor: 9.423

6.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

7.  An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.

Authors:  Robert J Luallen; Jianqiao Lin; Hu Fu; Karen K Cai; Caroline Agrawal; Innocent Mboudjeka; Fang-Hua Lee; David Montefiori; David F Smith; Robert W Doms; Yu Geng
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 8.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

Review 9.  Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.

Authors:  Kyriakos A Hassapis; Dora C Stylianou; Leondios G Kostrikis
Journal:  Viruses       Date:  2014-12-17       Impact factor: 5.048

10.  Potential of peptides as inhibitors and mimotopes: selection of carbohydrate-mimetic peptides from phage display libraries.

Authors:  Teruhiko Matsubara
Journal:  J Nucleic Acids       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.